AYTU BIOPHARMA, INC Prepaid Expense and Other Assets, Current
AYTU BIOPHARMA, INC (AYTU) had Prepaid Expense and Other Assets, Current of $5.81 million as of 2026-06-30, per its 10-K filed 2026-09-22.
Financial Statements › Notes
us-gaap:PrepaidExpenseAndOtherAssetsCurrent · last filed 2026-09-22
- 2026-06-30: Prepaid Expense and Other Assets, Current $5.81M.
- 2026-03-31: Prepaid Expense and Other Assets, Current $8.66M.
- 2025-12-31: Prepaid Expense and Other Assets, Current $6.64M.
- 2025-09-30: Prepaid Expense and Other Assets, Current $5.15M.
| Period end | Prepaid Expense and Other Assets, Current |
|---|---|
| 2026-06-30 | $5.81M 10-K · filed 2026-09-22 |
| 2026-03-31 | $8.66M 10-Q · filed 2026-05-13 |
| 2025-12-31 | $6.64M 10-Q · filed 2026-02-03 |
| 2025-09-30 | $5.15M 10-Q · filed 2025-11-13 |
| 2025-06-30 | $5.64M 10-K · filed 2026-09-22 |
| 2025-03-31 | $7.46M 10-Q · filed 2025-05-14 |
| 2024-06-30 | $5.10M 10-K · filed 2025-09-23 |
| 2021-03-31 | $6.80M 10-Q · filed 2021-05-17 |
| 2020-12-31 | $6.08M 10-Q · filed 2021-02-11 |
| 2020-09-30 | $3.68M 10-Q · filed 2020-11-12 |
| 2020-06-30 | $5.72M 10-Q · filed 2021-05-17 |
| 2020-03-31 | $4.83M 10-Q · filed 2020-05-15 |
| 2019-12-31 | $2.36M 10-Q · filed 2020-02-14 |
| 2019-09-30 | $573.20K 10-Q · filed 2019-11-14 |
| 2019-06-30 | $957.78K 10-K · filed 2020-10-06 |
| 2019-03-31 | $804.84K 10-Q · filed 2019-05-14 |
| 2018-12-31 | $944.77K 10-Q · filed 2019-05-14 |
| 2018-09-30 | $736.98K 10-Q · filed 2018-11-07 |
| 2018-06-30 | $440.01K 10-K · filed 2019-09-26 |
| 2018-03-31 | $896.90K 10-Q · filed 2018-05-14 |
| 2017-12-31 | $1.00M 10-Q · filed 2018-02-08 |
| 2017-09-30 | $262.06K 10-Q · filed 2017-11-09 |
| 2017-06-30 | $310.76K 10-K · filed 2018-09-06 |
| 2017-03-31 | $342.11K 10-Q · filed 2017-05-11 |
| 2016-12-31 | $436.57K 10-Q · filed 2017-02-09 |
| 2016-09-30 | $553.08K 10-Q · filed 2016-11-07 |
| 2016-06-30 | $215.56K 10-K · filed 2017-08-31 |
| 2015-06-30 | $370.89K 10-K · filed 2016-09-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |
| ARTELO BIOSCIENCES, INC. (ARTL) | United States | $0.023B | |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |